Welcome to our dedicated page for ENANTA PHARMACEUTICALS SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enanta Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer focused on small-molecule therapies for viral infections and immunological diseases. Its Form 8-K disclosures cover financial results, Regulation FD clinical-data materials, research and development updates, material agreements and capital-structure information for common stock traded under ENTA on the Nasdaq Global Select Market.
Proxy and annual meeting filings record governance matters including director elections, advisory executive compensation votes, auditor ratification and amendments to the 2019 Equity Incentive Plan. Other event disclosures also document patent litigation matters, including proceedings involving U.S. Patent No. 11,358,953 and Pfizer's COVID-19 antiviral Paxlovid.
Enanta Pharmaceuticals’ Chief Scientific Officer Or Yat Sun reported equity compensation activity. On February 12, 2026, Sun acquired 1,650 shares of common stock from performance share units tied to 2024–2025 R&D milestones and 5,225 shares from a relative total stockholder return unit award, both at $0 per share. On the same date, 3,413 shares were automatically forfeited at $14.25 per share to cover withholding taxes from settlement of these awards. Following these transactions, Sun directly owned 374,854 common shares.
Enanta Pharmaceuticals President and CEO Jay R. Luly, who is also a director, reported equity award activity in Enanta common stock. On February 12, 2026, he acquired 4,800 shares through performance share units tied to 2024-2025 R&D milestones and 15,200 shares from a relative total stockholder return unit award, both at no cash price. On the same date, 6,155 shares were automatically withheld and forfeited at $14.25 per share to cover tax obligations from these vestings. After these transactions, he directly beneficially owned 871,871 shares of Enanta common stock.
Deep Track Capital and affiliates report a 6.78% stake in Enanta Pharmaceuticals Inc. The group, including Deep Track Biotechnology Master Fund and David Kroin, beneficially owns 1,956,867 shares of Enanta common stock, with shared voting and dispositive power over all reported shares.
The ownership percentage is based on 28,862,601 Enanta common shares outstanding as of November 4, 2025, as referenced from the company’s Form 10-K. The reporting persons certify the shares are not held for the purpose of changing or influencing control of Enanta.
Enanta Pharmaceuticals, Inc. has filed a shelf registration statement on Form S-3 to offer and sell up to $150,000,000 of securities. The shelf covers common stock, preferred stock, debt securities, warrants and units that may be issued over time using prospectus supplements.
Enanta is a biotechnology company focused on small-molecule drugs for virology, including RSV, SARS‑CoV‑2, HCV and HBV, and for immunology indications such as atopic dermatitis, urticarias, asthma, COPD, CRSwNP and prurigo nodularis. Net proceeds from any offerings are intended for general corporate purposes, including R&D, commercialization, manufacturing, possible acquisitions and potential repayment or repurchase of future indebtedness or capital stock.
Enanta Pharmaceuticals reported royalty revenue of $18.6 million for the quarter ended December 31, 2025, up from $17.0 million a year earlier, driven by higher HCV sales of MAVYRET/MAVIRET from AbbVie.
Research and development expenses fell to $20.9 million from $27.7 million, mainly as RSV trials wound down, while general and administrative expenses decreased to $9.0 million from $12.8 million due to lower stock-based compensation and legal costs. Net loss narrowed to $11.9 million from $22.3 million, or $0.42 per share versus $1.05 per share.
Enanta closed an October 2025 public offering of 7.5 million shares at $10.00, generating $69.9 million in net proceeds. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $241.9 million, which the company believes will fund operations into fiscal 2029 while it advances RSV antivirals and multiple immunology programs.
Enanta Pharmaceuticals reported a narrower net loss for its fiscal first quarter ended December 31, 2025 while advancing its RSV and immunology pipelines. Revenue rose to $18.6 million from $17.0 million, driven by higher royalties on AbbVie’s MAVYRET®/MAVIRET® hepatitis C treatment.
Research and development expense fell to $20.9 million from $27.7 million and general and administrative expense declined to $9.0 million from $12.8 million, reflecting lower clinical, stock-based compensation and legal costs. Net loss improved to $11.9 million, or $0.42 per diluted share, from $22.3 million, or $1.05 per diluted share.
Enanta ended the quarter with $241.9 million in cash, cash equivalents and marketable securities and expects this, plus its retained portion of future royalty revenue, to fund operations into fiscal 2029. The company is conducting Phase 3 enabling work for RSV candidate zelicapavir, progressing RSV drug EDP-323, and advancing three immunology programs, including KIT inhibitor EDP-978 and STAT6 inhibitor EPS-3903, with multiple planned IND filings and data milestones in 2026.
Enanta Pharmaceuticals Inc. received an amended ownership report from Farallon-affiliated investors. The Schedule 13G/A (Amendment No. 7) shows multiple Farallon funds and related entities collectively reporting beneficial ownership positions in Enanta’s common stock.
The largest reported position is by Farallon Partners, L.L.C., which is listed with 2,640,779 Shares, representing 9.1% of the class. Several Farallon Individual Reporting Persons, including Joshua J. Dapice and others, are each reported as beneficial owners of 2,816,862 Shares, or 9.8% of the class, through their roles over the Farallon funds.
The amendment discloses governance changes in the Farallon General Partner structure. Effective January 1, 2026, Avner A. Husen became a member/manager of the relevant general partners and may be deemed a beneficial owner. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased those roles and may no longer be deemed beneficial owners. The group certifies the holdings are not for the purpose of changing or influencing control, and the filing is made under Rule 13d-1(c).
Enanta Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on March 11, 2026. Stockholders of record as of January 16, 2026, when 29,018,522 common shares were outstanding, can vote online, by phone, mail or during the webcast.
Two Class I directors, Bruce L.A. Carter and CEO Jay R. Luly, are nominated for new three-year terms. A key item is an amendment to the 2019 Equity Incentive Plan to add 1,600,000 shares to the share reserve, equal to 5.5% of common shares outstanding as of December 31, 2025. The board explains that equity awards are broadly granted, central to pay, and that Enanta’s three-year average net burn rate was 4.1% through fiscal 2025.
Stockholders are also asked to approve, on an advisory basis, 2025 compensation for named executive officers and to ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026. The proxy outlines board independence, committee structure and significant institutional ownership positions, including several holders above 5%.
Enanta Pharmaceuticals, Inc. received an amended Schedule 13G/A showing institutional investors led by Millennium entities holding a small, passive stake in its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 665,953 shares, representing 2.3% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 670,428 shares, also equal to 2.3% of the class, as of the event date December 31, 2025.
The filing states that these securities are not held for the purpose of changing or influencing control of Enanta and are reported on a Schedule 13G/A, which is used for passive ownership. The filing also confirms that the reporting persons each own 5% or less of Enanta’s outstanding common stock. A joint filing agreement among the reporting entities and Israel A. Englander is attached as an exhibit.